You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌禮制藥-B(01672.HK)治療免疫缺陷病毒藥物臨牀試驗獲美國批準
阿思達克 05-11 09:06
歌禮制藥-B(01672.HK)公佈,其ASC22(恩沃利單抗)臨牀試驗申請獲美國食品藥監局(FDA)批準,用於人類免疫缺陷病毒1型(HIV-1)感染者免疫重建/功能性治癒適應症。 ASC22(恩沃利單抗)是一種皮下注射的PD-L1單域抗體,具有重建慢性病毒感染者病毒特異性免疫應答的潛力。HIV-1感染者免疫重建/功能性治癒適應症是ASC22第二項獲美國FDA批準開展臨牀試驗的適應症,另一項爲慢性乙型肝炎功能性治癒適應症。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account